Cancer prevention: A new era beyond cyclooxygenase-2

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 1, 2005, Pages 1-8

  Rigas, Basil ^a,c   Kashfi, Khosrow ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARBONATE DEHYDRATASE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME C; GLUTATHIONE TRANSFERASE; IBUPROFEN; ICOSANOID; LICOFELONE; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; ROFECOXIB; SULINDAC; SURVIVIN;

APOPTOSIS; CANCER PREVENTION; CARDIOTOXICITY; CELL SPECIFICITY; COLON CANCER; COLON CARCINOGENESIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INDUCTION; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GENE ACTIVATION; HUMAN; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TARGET CELL; TUMOR CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; LACTONES; MEMBRANE PROTEINS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 23044498446     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.080564     Document Type: Review

References (66)

1. Badawi AF, Eldeen MB, Liu Y, Ross EA, and Badr MZ (2004) Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res 64:1181-1189.
2. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899.
3. Becerra CR, Frenkel EP, Ashfaq R, and Gaynor RB (2003) Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer 105:868-872.
4. Bennett A, Civier A, Hensby CN, Melhuish PB, and Stamford IF (1987) Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut 28:315-318.
5. Bjorkman DJ (1999) Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 107:3S-8S.
6. Blaine SA, Meyer AM, Hurteau G, Wick M, Hankin JA, Murphy RC, Subbaramaiah K, Dannenberg AJ, Geraci MW, and Nemenoff RA (2004) Targeted overexpression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice. Carcinogenesis 26:209-217.
7. Bol DK, Rowley RB, Ho CP, Pilz B, Dell J, Swerdel M, Kiguchi K, Muga S, Klein R, and Fischer SM (2002) Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res 62:2516-2521.
8. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, and Langenbach R (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705-4708.
9. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, and Giardiello FM (2002) Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122:641-645.
10. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, et al. (2004) Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 10:4062-4067.
11. Dannenberg AJ and Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4:431-436.
12. Ding H, Han C, Zhu J, Chen CS, and D'Ambrosio SM (2005) Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 113:803-810.
13. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, and Dubois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and carcinomas. Gastroenterology 107:1183-1188.
14. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, and Fitzgerald GA (2004) COX-2-derived prostacyclin confers atheroprotection on female mice. Science (Wash DC).
15. Eibl G, Takata Y, Boros LG, Liu J, Okada Y, Reber HA, and Hines OJ (2005) Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res 65:982-990.
16. Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351:1709-1711.
17. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, and Bell DA (2001) Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299:468-476.
18. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, and Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316.
19. Grosch S, Tegeder I, Niederberger E, Brautigam L, and Geisslinger G (2001) COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15:2742-2744.
20. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, and Rigas B (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52:237-245.
21. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, and Sugihara K (2003) A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 9:4756-4760.
22. Kawamori T, Rao CV, Seibert K, and Reddy BS (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409-412.
23. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA, and Geraci MW (2002) Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 62:734-740.
24. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP, and Geraci MW (2004) Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 64:5897-5904.
25. Kimmey MB (2004) Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. Am J Med 117 (Suppl 5A):72S-78S.
26. Kune G, Kune S, and Watson L (1988) Colorectal cancer risk, chronic illnesses, operations and medications: case-control results from the Melbourne Colorectal Cancer Study. Cancer Res 48:4399-4404.
27. Lin HJ, Lakkides KM, Keku TO, Reddy ST, Louie AD, Kau IH, Zhou H, Gim JS, Ma HL, Matthies CF, et al. (2002) Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 11:1305-1315.
28. Liou JY, Deng WG, Gilroy DW, Shyue SK, and Wu KK (2001) Colocalization and interaction of cyclooxygenase-2 with caveolin-1 in human fibroblasts. J Biol Chem 276:34975-34982.
29. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, and Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563-18569.
30. Maier TJ, Schilling K, Schmidt R, Geisslinger G, and Grosch S (2004) Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67:1469-1478.
31. Mao JT, Tsu IH, Dubinett SM, Adams B, Sarafian T, Baratelli F, Roth MD, and Serio KJ (2004) Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin Cancer Res 10:6872-6878.
32. Marx J (2001) Cancer research. Anti-inflammatories inhibit cancer growth-but how? Science (Wash DC) 291:581-582.
33. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, and Fitzgerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272-277.
34. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, and Furstenberger G (2002) Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 99:12483-12488.
35. Murakami M, Kambe-Ohkura T, and Kudo I (2002) Functional coupling between phospholipase A2S and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. Adv Exp Med Biol 507:15-19.
36. Niitsu Y, Takayama T, Miyanishi K, Nobuoka A, Hayashi T, Kukitsu T, Takanashi K, Ishiwatari H, Abe T, Kogawa T, et al. (2004) Chemoprevention of colorectal cancer. Cancer Chemother Pharmacol 54 (Suppl 1):S40-S43.
37. Nobuoka A, Takayama T, Miyanishi K, Sato T, Takanashi K, Hayashi T, Kukitsu T, Sato Y, Takahashi M, Okamoto T, et al. (2004) Glutathione-S- transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid. Gastroenterology 127:428-443.
38. D716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809.
39. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, et al. (2002) A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-860.
40. Qiao L, Kozoni V, Tsioulias GJ, Koutsos MI, Hanif R, Shiff SJ, and Rigas B (1995) Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1258:215-223.
41. Rigas B, Goldman IS, and Levine L (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122:518-523.
42. Rigas B and Shiff SJ (2000) Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med Hypotheses 54:210-215.
43. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883-890.
44. Schonbeck U, Sukhova GK, Graber P, Coulter S, and Libby P (1999) Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155:1281-1291.
45. Sheng HM, Shao JY, Morrow JD, Beauchamp RD, and Dubois RN (1998) Modulation of apoptosis and bcl-2 expression by prostaglandin E-2 in human colon cancer cells. Cancer Res 58:362-366.
46. Shiff SJ, Qiao L, Tsai LL, and Rigas B (1995) Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Investig 96:491-503.
47. Shiff SJ and Rigas B (1999) The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J ExpMed 190:445-450.
48. Shureiqi I and Lippman SM (2001) Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 61:6307-6312.
49. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Longterm Arthritis Safety Study. JAMA (J Am Med Assoc) 284:1247-1255.
50. Simmons DL, Botting RM, and Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387-437.
51. Singh G and Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 26:18-24.
52. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952.
53. Sun Y, Tang XM, Half E, Kuo MT, and Sinicrope FA (2002) Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62:6323-6328.
54. Takeda H, Sonoshita M, Oshima H, Sugihara K, Chulada PC, Langenbach R, Oshima M, and Taketo MM (2003) Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 63:4872-4877.
55. Teh SH, Hill AK, Foley DA, McDermott EW, O'Higgins NJ, and Young LS (2004) COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells. J Cell Biochem 91:796-807.
56. Thun MJ, Henley SJ, and Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 94:252-266.
57. Topper JN, Cai J, Falb D, and Gimbrone MA Jr (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93:10417-10422.
58. Turini ME and DuBois RN (2002) Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53:35-57.
59. Vane JR and Warner TD (2000) Nomenclature for COX-2 inhibitors. Lancet 356: 1373-1374.
60. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, and Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568.
61. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, and Burton J (2002) Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62:2029-2033.
62. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, and Klebe G (2004) Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 47:550-557.
63. Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L, Kashfi K, and Rigas B (2003) Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 63:7613-7618.
64. Winde G, Schmid KW, Brandt B, Muller O, and Osswald H (1997) Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 40:1156-1168.
65. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, and Bunte H (1995) Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 38:813-830.
66. Yamaguchi K, Lee SH, Eling TE, and Baek SJ (2004) Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J Biol Chem 279:49617-49623.